| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Rallybio Corp
13D/A
Amendment 3
RLYB · 75120L209
|
0% |
5/6/2026
Event 5/4/2026
|
|||
| 5AM Ventures V, L.P. | 0% | ||||
| 5AM Partners V, LLC | 0% | ||||
| 5AM Opportunities I, L.P. | 0% | ||||
| 5AM Opportunities I (GP), LLC | 0% | ||||
| Andrew J. Schwab | 0% | ||||
| Kush Parmar | 0% | ||||
| Scott M. Rocklage | 0% | ||||
|
Rallybio Corp
13D/A
Amendment 2
RLYB · 75120L209
|
5.5% |
2/27/2026
Event 2/25/2026
|
|||
| 5AM Ventures V, L.P. | 2.6% | ||||
| 5AM Partners V, LLC | 2.6% | ||||
| 5AM Opportunities I, L.P. | 3.0% | ||||
| 5AM Opportunities I (GP), LLC | 3.0% | ||||
| Andrew J. Schwab | 5.5% | ||||
| Kush Parmar | 5.5% | ||||
| Scott M. Rocklage | 2.6% | ||||
|
Entrada Therapeutics, Inc.
13D/A
Amendment 1
TRDA · 29384C108
|
10.8% |
11/18/2025
Event 11/14/2025
|
|||
| 5AM Ventures V, L.P. | 7.8% | ||||
| 5AM Partners V, LLC | 7.8% | ||||
| 5AM Opportunities I, L.P. | 2.9% | ||||
| 5AM Opportunities I (GP), LLC | 2.9% | ||||
| Andrew J. Schwab | 10.6% | ||||
| Kush Parmar | 10.8% | ||||
| Scott M. Rocklage | 7.8% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.